Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06746285 · ClinicalTrials.gov registry record · NA
Evaluating the Impact of Synbiotic Supplementation on Infants and Toddlers
A NA study of Gastrointestinal Tolerance of Probiotics in Infants, sponsored by Persephone Biosciences.
- Active
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06746285 is a NA study of Gastrointestinal Tolerance of Probiotics in Infants that is active but no longer recruiting, run by Persephone Biosciences. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06746285, a NA study of Gastrointestinal Tolerance of Probiotics in Infants, is active but no longer recruiting, sponsored by Persephone Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Background and Significance: Bifidobacterium longum subspecies infantis (B. infantis) and other infant associated Bifidobacterium (such as Bifidobacterium longum subspecies longum and Bifidobacterium breve) are known to be important bacteria in the infant gut microbiome. A lack of Bifidobacterium in the infant gut may lead to disordered development of the infant microbiome and immune system, which can contribute to the development of gastrointestinal issues, pathogenic infections, and immune-related conditions including allergic disease and autoimmune disorders. The investigators hypothesize that establishing Bifidobacterium in the infant gut through delivery of a synbiotic, containing bifidobacterium and human milk oligosaccharides (HMOs; Bifidobacterium's primary nutrient source) may modulate the microbiome and correct this disruption. Research Question: Does synbiotic supplementation on infants and toddlers of various ages alter the gut microbiome as measured by GI-tolerance, fecal microbiome composition, and fecal metabolic profile? Objectives: * Demonstrate shifts in microbiome composition and metabolism * Demonstrate tolerance by observing neutral or positive shifts in GI related behaviors Study Design Overview: Participants Infants aged 2-24 months will be enrolled to evaluate the ability of a synbiotic (human milk oligosaccharide + a Bifidobacterium blend (B. infantis, B. longum, and B. breve)) to modulate the gut microbiome. Infants will be randomly split into two cohorts, one that receives synbiotic supplementation and one that receives a placebo control (lactose). Initially, only ages 12-24 months will be enrolled (first 25 participants), and a safety review will be performed prior to enrolling younger infants. Cohorts * Cohort 1 (supplementation) participants will be aged 2 months to 24 months. They will receive synbiotic supplementation for 1 month. * Cohort 2 (no supplementation) participants will be aged 2 months to 24 months. Will receive p
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Synbiotic Supplement
- DIETARY_SUPPLEMENT Lactose (inactive placebo)
Study Locations (1)
California
- Persephone Biosciences - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06746285
The ClinicalTrials.gov registry entry for NCT06746285 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Persephone Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Tolerance of Probiotics in Infants appearing as the primary indexed condition, and to 2 interventions - of which Synbiotic Supplement is the first listed.
NCT06746285 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06746285 about?
NCT06746285 is a clinical study titled "Evaluating the Impact of Synbiotic Supplementation on Infants and Toddlers". Background and Significance: Bifidobacterium longum subspecies infantis (B. infantis) and other infant associated Bifidobacterium (such as Bifidobacterium longum subspecies longum and Bifidobacterium breve) are known to be important bacteria in the infant gut microbiome. A lack of Bifidobacterium i...
What is the current status of trial NCT06746285?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2025-01-01. Estimated completion is 2025-12-31.
What conditions does trial NCT06746285 study?
This clinical trial studies the following conditions: Gastrointestinal Tolerance of Probiotics in Infants.
What interventions are being tested in trial NCT06746285?
The interventions under investigation include: Synbiotic Supplement (DIETARY_SUPPLEMENT), Lactose (inactive placebo) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06746285?
This trial is sponsored by Persephone Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06746285 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.